Categories
Mankind Pharma Limited — Board Meeting, 19-05-2026: Outcome of Board Meeting
19-05-2026 · 07:13 pm
Mankind Pharma's board approved Q4 & full-year consolidated results: revenue ₹13,277.64 Cr, Q4 profit ₹554.35 Cr. They approved ₹500 Cr investment in a subsidiary for expansion. Top executives waived commissions to boost cash. Whole-Time Director re-appointed; CIO resigned.
No comments yet. Be the first to comment!